Contrasting Lexaria Bioscience (LEXX) & The Competition

Lexaria Bioscience (NASDAQ:LEXX) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Lexaria Bioscience to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Lexaria Bioscience and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexaria Bioscience	$194,000.00	-$11.90 million	-0.68
Lexaria Bioscience Competitors	$4.62 billion	$3.22 billion	545.49

Lexaria Bioscience’s peers have higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Lexaria Bioscience and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Lexaria Bioscience Competitors	-2,380.91%	-221.73%	-15.99%

Volatility & Risk

Lexaria Bioscience has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Lexaria Bioscience’s peers have a beta of -4.29, meaning that their average share price is 529% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Lexaria Bioscience and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1	0	1	0	2.00
Lexaria Bioscience Competitors	7764	13847	25695	1031	2.41

Lexaria Bioscience currently has a consensus target price of $22.50, indicating a potential upside of 544.70%. As a group, “Pharmaceuticals” companies have a potential upside of 23.91%. Given Lexaria Bioscience’s higher probable upside, research analysts clearly believe Lexaria Bioscience is more favorable than its peers.

Summary

Lexaria Bioscience peers beat Lexaria Bioscience on 9 of the 13 factors compared.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.